United Therapeutics
Update in progressUTHR (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
United Therapeutics Corporation develops and markets therapies for chronic and life-threatening diseases in the United States and globally. Its products include Tyvaso DPI and Nebulized Tyvaso (treprostinil), Remodulin injections, Orenitram (treprostinil tablet), and Adcirca (tadalafil) for pulmonary arterial hypertension. It markets Unituxin for high-risk neuroblastoma and Remunity Pump, and pursues programs such as Ralinepag, RemunityPRO, xenotransplantation, and regenerative medicine. Collaborations include DEKA, MannKind, and Arena. Founded 1996, Silver Spring, MD.
Company score
- Sentiment
- 0.52
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.02
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.44
- Governance
- 0.18
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.17
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.35
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
- Founded1996
- Employees1,400
- Websitewww.unither.com
Identifiers
- ISINUS91307C1027
- FIGIBBG000BV4XJ1
- LEI5299005C4HZL4UWROC14
- CUSIP91307C102
- CIK0001082554